Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
About Anika Therapeutics Inc.
Anika Therapeutics Inc. (NASDAQ: ANIK) is a global medical technology company specializing in joint preservation and early intervention orthopedic care. Leveraging its proprietary expertise in hyaluronic acid (HA) technology, Anika develops and delivers innovative, minimally invasive products that address critical needs in osteoarthritis pain management, regenerative solutions, and sports medicine. Headquartered near Boston, Massachusetts, Anika’s mission is to empower patients worldwide to restore active living through groundbreaking medical advancements.
Core Business Areas
Anika’s operations are strategically focused on high-growth segments within orthopedics:
- Osteoarthritis (OA) Pain Management: The company offers viscosupplementation products such as Monovisc® and Orthovisc®, which are market leaders in the U.S. for managing OA-related joint pain. Internationally, Anika is expanding its market share with Cingal®, a next-generation combination therapy awaiting FDA approval in the U.S.
- Regenerative Solutions: Anika’s HA-based regenerative products, including the Integrity Implant System, are designed to enhance tendon healing and soft tissue repair. The company’s pipeline includes Hyalofast®, an HA cartilage repair solution poised to address the $1 billion U.S. cartilage repair market by 2026.
- Sports Medicine: Through its innovative implant systems, Anika provides solutions for complex tendon and ligament repairs, supporting accelerated recovery and improved patient outcomes.
Business Model and Market Strategy
Anika employs a dual-channel revenue model:
- Commercial Channel: The company directly manages sales, marketing, and pricing for its products, particularly in international markets and its Regenerative Solutions portfolio. This channel drives growth through high-margin, differentiated product offerings.
- OEM Channel: Anika partners with leading medical device companies for the development and manufacturing of products like viscosupplements. This channel provides a stable revenue foundation and enables investment in R&D.
Anika’s strategic focus includes divesting non-core assets, such as Arthrosurface and Parcus Medical, to concentrate resources on its HA-driven technologies and high-growth opportunities in regenerative medicine and pain management.
Innovation and Competitive Positioning
Anika differentiates itself through its deep expertise in HA-based technologies, which are integral to its regenerative and pain management solutions. The company’s flagship products, including the Integrity Implant System, showcase its commitment to advancing minimally invasive care. By addressing unmet needs in orthopedics and leveraging its proprietary HA platform, Anika is well-positioned to capture significant market share in the $4 billion global market for joint preservation and regenerative solutions.
Future Outlook
With a robust pipeline that includes the U.S. launch of Hyalofast by 2026 and ongoing progress toward FDA approval for Cingal, Anika is poised for sustainable growth. The company’s strategic initiatives to streamline operations and focus on high-value programs align with its long-term vision of maximizing shareholder value and improving patient outcomes globally.
Anika Therapeutics (NASDAQ: ANIK) has received 510(k) clearance from the FDA for its Tactoset® Injectable Bone Substitute. This clearance allows Tactoset to augment hardware and support bone fragments during surgical procedures. With this expanded indication, the addressable market now includes augmentation of suture anchor fixation, a significant growth area for Anika. Tactoset, launched in Q4 2019, is a calcium phosphate-based biocompatible bone graft that enhances surgical outcomes. Anika plans to actively market this indication starting in October 2021.
Anika Therapeutics (NASDAQ: ANIK) announced their participation in the Morgan Stanley 19th Annual Global Healthcare Conference, taking place virtually on September 15, 2021, at 2:00 p.m. ET. Dr. Cheryl Blanchard, CEO, and Michael Levitz, CFO, will engage in a fireside chat. Investors can listen to the live audio webcast on Anika’s website under the Investor Relations section, with an archive available later. Anika focuses on early intervention orthopedics, creating minimally invasive products to enhance patient active living.
Anika Therapeutics (NASDAQ: ANIK) will showcase its complete joint preservation and restoration portfolio at the 2021 AAOS Annual Meeting in San Diego, California, from September 1-3. The company, now integrated with Arthrosurface and Parcus Medical, aims to lead in early intervention orthopedics. Featured products include the OVOMotion Total Shoulder System and Tactoset Injectable Bone Substitute. Notably, the OVOMotion system shows no loosening after 4,000 cycles. Anika's focus on innovative solutions addresses unmet needs in orthopedic care.
Anika Therapeutics reported a 24% year-over-year revenue growth for Q2 2021, totaling $38.1 million, recovering from earlier COVID impacts. Joint Preservation and Restoration revenue surged 79% to $11.9 million, while Joint Pain Management grew 9% to $24.3 million. The company expects full-year revenue growth of 11-14%, up from prior guidance. Net income improved to $6.5 million or $0.45 per diluted share, aided by a $9.8 million reduction in contingent consideration. Despite these gains, uncertainty due to the COVID pandemic remains a headwind.
On July 19, 2021, Anika Therapeutics (NASDAQ: ANIK) announced plans to issue its Q2 2021 financial results after market close on August 5, 2021. An investor conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results and business highlights. The call will be accessible via toll-free and international numbers, and will also be available through a live audio webcast on Anika's Investor Relations website. Anika is focused on early intervention in orthopedics, providing minimally invasive solutions for joint preservation.
Anika Therapeutics (NASDAQ: ANIK) has initiated a limited launch of its WristMotion Total Wrist Arthroplasty (TWA) System, aimed at alleviating pain and restoring motion in arthritic wrist joints. The first surgery was performed on June 30, 2021, by Dr. Arnold-Peter C. Weiss at University Orthopedics, Rhode Island. The system, which received FDA clearance in October 2020, replaces both the radial and carpal sides of the wrist joint. The limited launch will progress to a full nationwide launch in Fall 2021, with presentations at major orthopedic meetings.
Anika Therapeutics (NASDAQ: ANIK) held its 2021 Virtual Investor Day, outlining a multi-year Joint Preservation strategy aimed at accelerating revenue growth and enhancing profitability. The company raised its 2021 revenue growth forecast to 10%-13% and reiterated a target to double 2019 revenues to approximately $230 million by 2024, focusing on the joint preservation market, valued at over $8 billion. Anika's leadership emphasized leveraging HA-based technologies and expanding its commercial presence to achieve these goals while navigating delays in pivotal trials due to COVID-19.
Anika Therapeutics, a global joint preservation company, will host its 2021 Virtual Investor Day on June 3, 2021, starting at 9:00 AM EDT. Key executives, including President Cheryl Blanchard and CFO Mike Levitz, will present an overview of the company's business strategy, product portfolio, R&D pipeline, and financial objectives. The event will feature presentations followed by a Q&A session with senior leaders. A webcast will be available on the company’s Investor Relations website for replay.
Anika Therapeutics reported Q1 2021 revenue of $34.3 million, down 3% year-over-year. Joint Preservation revenue surged 55% to $12.2 million, driven by acquisitions, while Joint Pain Management dropped 24% to $19.3 million, mainly due to COVID impacts. The company's revenue mix is shifting positively, with Joint Preservation now 36% of total revenue. Net income fell to $2.8 million ($0.20 per share) versus $5.8 million ($0.40 per share) last year. For 2021, Anika expects upper 20% to low 30% growth in Joint Preservation, projecting overall revenue growth in the high single to low double digits.
Anika Therapeutics (NASDAQ: ANIK) announced participation in three upcoming virtual investor conferences this May. Dr. Cheryl Blanchard, CEO, and Michael Levitz, CFO, will present at the following events: the 16th Annual Canaccord Genuity Musculoskeletal Conference on May 20, starting at 9:00 a.m. ET, the UBS Global Healthcare Virtual Conference on May 25, starting at 8:00 a.m. ET, and Oppenheimer’s MedTech Summit with a pre-recorded session on May 26. All presentations will be accessible via Anika's Investor Relations website.
FAQ
What is the current stock price of Anika Therapeutics (ANIK)?
What is the market cap of Anika Therapeutics (ANIK)?
What does Anika Therapeutics specialize in?
What are Anika’s key product offerings?
How does Anika generate revenue?
What makes Anika’s technology unique?
What is Anika’s growth strategy?
Who are Anika’s competitors?
What is Hyalofast, and when will it launch in the U.S.?
What challenges does Anika face in its markets?
What is the significance of Anika’s Regenerative Solutions portfolio?
Where is Anika Therapeutics headquartered?
